Weight Loss Medications in 2026: Ozempic, Wegovy, Mounjaro & What You Need to Know

The landscape of obesity treatment has been fundamentally transformed by a new class of medications — GLP-1 receptor agonists and dual GIP/GLP-1 agonists. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are producing weight loss results that were previously only achievable with bariatric surgery. At Advantixx Pharmacy in Las Vegas, we've seen enormous patient interest in these medications — and enormous confusion about how they work, who qualifies, and what to expect.

How GLP-1 Medications Work

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It stimulates insulin release, suppresses glucagon, slows gastric emptying (so you feel full longer), and — critically — acts on the brain's appetite centers to reduce hunger and food cravings. GLP-1 receptor agonists mimic and amplify these effects.

Tirzepatide (Mounjaro, Zepbound) adds a second mechanism — it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, which appears to produce even greater weight loss than GLP-1 alone. In clinical trials, tirzepatide produced average weight loss of 20–22% of body weight.

The Key Medications: What's the Difference?

• Ozempic (semaglutide 0.5–2mg) — FDA-approved for type 2 diabetes; widely used off-label for weight loss; weekly injection
• Wegovy (semaglutide 2.4mg) — FDA-approved specifically for chronic weight management; weekly injection; higher dose than Ozempic
• Rybelsus (semaglutide 7–14mg) — oral tablet form of semaglutide; FDA-approved for type 2 diabetes
• Mounjaro (tirzepatide 2.5–15mg) — FDA-approved for type 2 diabetes; dual GIP/GLP-1 agonist; weekly injection
• Zepbound (tirzepatide 2.5–15mg) — FDA-approved specifically for chronic weight management; same drug as Mounjaro

Who Qualifies for Weight Loss Medications?

FDA-approved weight loss medications (Wegovy, Zepbound) are indicated for adults with a BMI of 30 or higher (obesity), or a BMI of 27 or higher (overweight) with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol. A prescription from a licensed healthcare provider is required.

What Results Can You Expect?

Clinical trial results are impressive: Wegovy produced average weight loss of 15% of body weight over 68 weeks. Zepbound produced 20–22% average weight loss. However, real-world results vary. These medications work best when combined with lifestyle changes — reduced calorie intake and increased physical activity. Weight typically returns if the medication is stopped.

Side Effects: What Patients Experience

• Nausea — the most common side effect, especially when starting or increasing dose; usually improves over time
• Vomiting and diarrhea — less common; often dose-dependent
• Constipation — affects some patients, particularly with tirzepatide
• Decreased appetite — the intended effect, but can be extreme in some patients
• Injection site reactions — mild redness or bruising at injection site
• Rare but serious: pancreatitis, gallbladder disease, thyroid tumors (in animal studies — significance in humans unclear)

The Cost Reality and Insurance Coverage

These medications are expensive — Wegovy and Zepbound list prices are $1,000–$1,400 per month without insurance. Coverage varies significantly by insurance plan. Medicare currently does not cover weight loss medications (though this may change). Many commercial plans cover them with prior authorization. Manufacturer savings cards can reduce costs for eligible patients.

At Advantixx Pharmacy, we help patients navigate insurance coverage, manufacturer assistance programs, and prior authorization processes for GLP-1 medications. Call 702.665.8797 to discuss your options.